Simulation-Based Analysis of the Impact of Renal Impairment on the Pharmacokinetics of Highly Metabolized Compounds
Renal impairment (RI) is a highly prevalent disease which can alter the pharmacokinetics (PK) of xenobiotics, including those that are predominately metabolized. The expression and activity of drug metabolizing enzymes (DMEs) and protein binding of compounds has been demonstrated to be affected in R...
Main Authors: | Kristin E. Follman, Marilyn E. Morris |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4923/11/3/105 |
Similar Items
-
Determination of isotretinoin in human plasma: Application to pharmacokinetic study
by: Nisreen F. Abo-Talib, et al.
Published: (2012-12-01) -
A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia
by: Samia Kalsoom, et al.
Published: (2024-02-01) -
Pharmacokinetics, pharmacodynamics, and safety of ciprofol emulsion in Chinese subjects with normal or impaired renal function
by: Jun Tao, et al.
Published: (2023-11-01) -
Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics
by: Kit Wun Kathy Cheung, et al.
Published: (2024-04-01) -
Changes in the Pharmacokinetics and Pharmacodynamics of Sildenafil in Cigarette and Cannabis Smokers
by: Mohammed Murtadha, et al.
Published: (2021-06-01)